Decoy Therapeutics adds Moderna executive Patricia Gauthier to board

Decoy Therapeutics Inc.
Moderna

Decoy Therapeutics Inc.

DCOY

0.00

Moderna

MRNA

0.00
  • Decoy Therapeutics stockholders elected Patricia Gauthier as a Class II director at the July 14, 2026 annual meeting.
  • Gauthier has been Moderna’s senior vice president and regional head for Australia, Canada, and the UK since 2025.
  • She previously served as general manager of Moderna Canada, building the affiliate and supporting delivery of more than 50 million COVID-19 vaccine doses.
  • Rick Pierce and Jon Lieber were re-elected as Class II directors.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Decoy Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607150924PR_NEWS_USPR_____NE05192) on July 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.